- Home
- INIO vs INSM Comparison
INIO vs INSM Comparison
Compare INIO & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INIO | INSM |
|---|---|---|
| Founded | N/A | 1988 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 22.4B |
| IPO Year | 2026 | 2000 |
Fundamental Metrics
Financial Performance| Metric | INIO | INSM |
|---|---|---|
| Price | $19.60 | $127.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $201.17 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $182.31 |
| Revenue Next Year | N/A | $65.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.04 | $90.39 |
| 52 Week High | $42.95 | $212.75 |
Technical Indicators
Market Signals| Indicator | INIO | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 57.07 |
| Support Level | $19.04 | $122.21 |
| Resistance Level | $24.41 | $137.70 |
| Average True Range (ATR) | 1.30 | 4.42 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 10.06 | 72.92 |
Price Performance
Historical ComparisonAbout INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.